new treatment

At the Brain Cancer Centre, Royal Melbourne Hospital, WEHI, Peter MacCallum Cancer Centre, Victorian brain cancer researchers have achieved a global-first, using an innovative process to learn how a new drug suppresses tumour activity and provides hope to patients with low-grade gliomas (LGG). 

It’s the first clinical trial to be conducted through the pioneering Brain Perioperative platform, or “BrainPOP”, which is led by The Brain Cancer Centre and funded by the Victorian Government.

Dementia Australia has welcomed the publication of the results of a trial showing that a new drug, donanemab, has been able to slow the progression of symptoms of early Alzheimer’s disease.  Dementia Australia CEO Maree McCabe AM said this drug was an exciting new development and another step forward in expanding the number of treatments for dementia.

“These results provide much needed hope for people who are developing symptoms, have mild cognitive impairment or who are in the early stages of Alzheimer’s disease,” Ms McCabe said.